Brand dynamics

Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health

Integrated pharmaceutical companies accelerate growth; Healthspring and Lizhu Pharmaceutical's valsartan capsules successfully pass evaluation

Published Time:

2022-06-02

On the evening of June 1, Jiankangyuan (600380.SH) announced that its holding subsidiary, Lizhu Pharmaceutical Group Co., Ltd.'s wholly-owned subsidiary, Lizhu Pharmaceutical Factory (hereinafter referred to as "Lizhu Pharmaceutical Factory"), received the "Drug Supplement Application Approval Notice" issued by the National Medical Products Administration. Lizhu Pharmaceutical Factory's Valsartan Capsules passed the consistency evaluation of quality and efficacy of generic drugs.

 

Since the implementation of the generic drug consistency evaluation policy, most domestic pharmaceutical companies have actively participated. Generic drugs and innovative drugs are developing in parallel. While leading pharmaceutical companies are accelerating their innovative transformation, they are also continuously promoting their generic drug business. As of the announcement date, the company has cumulatively invested approximately RMB 17,168,200 in direct R&D expenses for the Valsartan Capsules consistency evaluation.

 

Valsartan Capsules is a Class A variety in the "National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance Drug Catalog" (Medical Insurance [2021] No. 50), used to treat mild to moderate primary hypertension. Passing the consistency evaluation will help the company improve the market competitiveness of its drugs and contribute an important growth point to future sales revenue.

 

Currently, a total of 10 companies in China (excluding the originator) hold production licenses for Valsartan Capsules. Among them, 8 companies, including Lizhu Pharmaceutical Factory, have passed the consistency evaluation of this product. According to IQVIA's sample statistical estimation data, the terminal sales amount of Valsartan oral preparations in China in 2021 was approximately RMB 556 million.

 

After years of development and accumulation, Jiankangyuan has become a comprehensive pharmaceutical group focusing on innovative research. Jiankangyuan stated that the company has always adhered to technological innovation as its strategic foundation and aims to build a high-barrier complex dosage form technology platform. It has currently deployed innovative high-barrier complex dosage form R&D technology platforms represented by inhalation administration, antibody technology, and sustained-release microspheres. Especially in the inhalation preparation sector, Jiankangyuan has broken through the barriers of R&D, approval, and production, and its flagship products such as "Shutanlin," "Lishutu," and "Wushu" have been successively launched, leaving a strong mark on the history of high-end inhalation preparation development in China.

 

In addition, Jiankangyuan, leveraging internal and external resources, has focused on developing green pharmaceutical technologies using cutting-edge technologies such as AI assistance and synthetic biology. It utilizes AI technology to better serve R&D innovation, contributing to the development and upgrading of China's pharmaceutical and healthcare industry. At the same time, it aims to reduce environmental pollution and resource consumption from the source, effectively contributing to the smooth achievement of "dual carbon" goals, demonstrating the strong strength and vision of a comprehensive innovative pharmaceutical company.

 

Source: Every day Economic News